Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Suicide Risk in Veterans with MDD
NCT06854224Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suvorexant in major depressive disorder (MDD). Primary endpoint: Implicit Association Tests at Week 5. Started Sep 2025; status: recruiting.
02
Drugs
suvorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06854224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854224.